VRC Clinical Trial Publications

The Vaccine Research Center Clinical Trials Program evaluates investigational vaccines and monoclonal antibodies (mAb) in clinical studies.  Data generated from the safety and immunogenicity assessments are analyzed and presented in study publications. Below is a listing of recent publications of VRC  clinical trials.  

VRC 311: Phase 1 Chikungunya Virus VLP Vaccine Clinical Trial 
A Phase 1 open label, dose-escalation clinical trial to evaluate the safety and immunogenicity of a virus-like particle (VLP) chikungunya vaccine in healthy adults

VRC 313: Virus-like particle (VLP) vaccine against western, eastern, and Venezuelan equine encephalitis viruses
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

VRC 704: Phase 2 Chikungunya Virus VLP Vaccine Clinical Trial
A phase 2 randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a chikungunya virus-like particle vaccine in healthy adults

VRC 207: Ebola cAd3 Vaccines Clinical Trial 
A Phase 1/1b, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, and immunogenicity of Ebola chimpanzee adenovirus vector (cAd3) vaccines in healthy adults

VRC 608: Ebola mAb114 Clinical Trial
An open-label Phase 1 study of the safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein

VRC 601: HIV mAb VRC01 Clinical Trial in HIV-Infected Adults
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

VRC 602: HIV mAb VRC01 Clinical Trial in Healthy Adults 
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

VRC 603: AAV8-vectored VRC07 HIV mAb 
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

VRC 605: HIV mAb VRC07-523LS Clinical Trial
A Phase 1 dose-escalation clinical trial assessing safety and pharmacokinetics of broadly neutralizing human monoclonal antibody VRC07-523LS in healthy adults

VRC 606: HIV mAb VRC01LS Clinical Trial
A Phase 1 open-label clinical trial assessing safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS in healthy adults

VRC 900: Licensed HPV Vaccine Comparison Trial
Comparison of adaptive and innate immune responses induced by licensed vaccines for HPV

VRC 900: Licensed HPV Vaccine Comparison Trial
Lymph node activation by PET/CT following vaccination with licensed vaccines for HPV

VRC 315: Influenza DNA Prime Clinical Trial
A Phase 1 open-label, randomized study of H7 influenza prime-boost regimens in healthy adults

VRC 316: Influenza H2 Ferritin Nanoparticle Vaccine
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

VRC 702: Influenza Seasonal DNA Prime in Children and Adolescents Clinical Trial
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A Phase 1 randomized clinical trial

VRC  703: Influenza Seasonal DNA Prime ID or IM Clinical Trial
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally (ID) or intramuscularly (IM) in healthy adults: An open-label randomized Phase 1 clinical trial.

VRC 312 & 314: Malaria Vaccine Clinical Trials
Protection against malaria at one year and immune correlates following Plasmodium falciparum sporozoite (PfSPZ) vaccination

VRC 612: Malaria mAb CIS43LS Clinical Trial
A Phase 1, open-label, dose escalation study to evaluate the dose, safety, tolerability and protective efficacy of an anti-malaria human monoclonal antibody, VRC -MALMAB0100-00-AB (CIS43LS)

VRC 317: Stabilized RSV Protein Vaccine Clinical Trial
A Phase 1 randomized, open-label clinical trial to evaluate dose, safety, tolerability, and immunogenicity of a stabilized prefusion RSV F subunit protein vaccine in healthy adults

VRC 319 & 320: Zika DNA Vaccine Clinical Trials
Randomized, open-label, Phase 1 clinical trials assessing the safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults

Content last reviewed on